Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Net Cash Flow (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Net Cash Flow for 6 consecutive years, with -$2.3 million as the latest value for Q4 2021.

  • Quarterly Net Cash Flow fell 167.9% to -$2.3 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2021, up 112.15% year-over-year, with the annual reading at -$2.5 million for FY2025, 723.68% down from the prior year.
  • Net Cash Flow for Q4 2021 was -$2.3 million at ENDRA Life Sciences, down from -$2.3 million in the prior quarter.
  • The five-year high for Net Cash Flow was $9.6 million in Q1 2021, with the low at -$3.1 million in Q1 2020.
  • Average Net Cash Flow over 5 years is $465829.0, with a median of -$1.2 million recorded in 2017.
  • The sharpest move saw Net Cash Flow tumbled 21648.18% in 2018, then skyrocketed 39075.66% in 2020.
  • Over 5 years, Net Cash Flow stood at -$1.4 million in 2017, then surged by 524.13% to $5.8 million in 2018, then plummeted by 33.17% to $3.9 million in 2019, then dropped by 11.92% to $3.4 million in 2020, then plummeted by 167.9% to -$2.3 million in 2021.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$2.3 million, -$2.3 million, and -$2.8 million for Q4 2021, Q3 2021, and Q2 2021 respectively.